VCCircle is back with the second edition of its immensely successful healthcare investment summit which will attempt to peel the various layers of this compelling vertical story, try to discover new sub-plots and also create a common language for medico-entrepreneurs and investors.

The reasons for deep-diving into this vertical are several: Indian healthcare is perhaps on the threshold of a golden age with rising income levels, penetration of insurance, increased life expectancy and lifestyle diseases, greater awareness and, more importantly, higher wallet spends on well-being are the macro trends making this sector red-hot in terms of attractiveness.

While rural and primary healthcare is still largely in the public domain, private sector healthcare delivery is clearly leading trends in urban India and is now gradually spreading its wings to tier II and tier III cities and towns. From the basic pill you pop to the blood sugar test to diagnostics chains, daycare surgery centres, specialty maternity clinics, air ambulance services, generic implantable stent-makers, the spread is vast and throws up interesting niches in this multi-layered theme.

The sheer market size coupled with its non-cyclical and recession-proof nature make this sector a winner. Sample this data: India’s healthcare sector is expected to grow at 23% annually to become a $77-billion industry by 2012 with diagnostics contributing $2.5 billion, a Yes Bank-Assocham report says. Alongside this staggering growth is a rather worrying statistic on the demand-supply mismatch in basic healthcare in India. At present, there are only nine beds per 10,000 people in India as opposed to the world average of 40 beds per 10,000. That is the kind of opportunity set for healthcare play in India.

It is in this backdrop that the VCCircle Healthcare Investment Summit 2010, slated to be held on September 3 in Mumbai, seeks to touch upon issues such as: Where is consolidation in generic pharma play headed? What is the right healthcare delivery model for India-Hospitals like Apollo or Fortis, specialized chains like HCG or a combination of both? What are the challenges to scaling diagonstic delivery chains? What are the new opportunities in medical devices space? Will genericisation in devices such as implantables (stents etc) mirror generic drug industry in terms of scaling and deal trends? Are investors prepared for long gestation play in healthcare particularly mainline hospitals? Are doctors willing to handle power point presentations along with their steths? Is real estate one of the biggest challenges to scale in healthcare delivery? Are Indian hospitals chasing the Asian story?

Be sure to hear what healthcare CEOs and medico-entrepreneurs have to say on opportunities in this non-cyclical business. To get a master health check on deal-making in this space, 30% off on ticket price of Rs 15,000 is available till July 23. See full details on

Speakers confirmed till now

RAJIV SHARMA, CEO, Sterling Addlife India Limited

G S K VELU, MD, Metropolis Health Services Ltd.

HARI BUGGANA, MD, Evolvence India Life Sciences Fund

MAYUR ABHAYA SRISRIMAL, Executive Director, LifeCell International

SANJAY SINGH, Founder, Swas Healthcare Pvt. Ltd

B.BHASKAR RAO, MD & CEO, Krishna Institute of Medical Sciences Ltd

SIDDHARTH DHONDIYAL, Vice President, India Value Fund Advisors


B N MANOHAR, CEO, Stempeutics Research Pvt Ltd

DARIUS D PANDOLE, Partner, New Silk Route Advisors

DR AJAY AGARWAL, MD, Diwan Chand Medical Services Pvt Ltd

K RAVINDRANATH, Chairman & MD, Global Hospitals Ltd

DR ALOK ROY, CMD, Medica Synergie Pvt Ltd

SANJAY ARTE, Partner, India Value Fund Advisors

(More panelists and keynote speakers joining)

Leave Your Comment(s)